Published in Eur J Clin Microbiol on June 01, 1985
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother (1990) 1.38
Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother (1999) 1.24
Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. Antimicrob Agents Chemother (1995) 1.20
Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00
Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother (1992) 0.96
Pharmacokinetics of ciprofloxacin. Infection (1988) 0.91
Effects of two cations on gastrointestinal absorption of ofloxacin. Antimicrob Agents Chemother (1991) 0.91
Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother (1996) 0.91
Fluoroquinolones: interaction profile during enteral absorption. Drugs (1993) 0.91
The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol (1993) 0.89
Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother (1994) 0.87
Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1991) 0.87
Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother (1989) 0.85
Antacids and ciprofloxacin pharmacokinetics. Antimicrob Agents Chemother (1988) 0.80
Effect of renal function on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1990) 0.79
Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother (1995) 0.76
Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1991) 0.75
Antibiotic therapy in aging patients. Bull N Y Acad Med (1987) 0.75
Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother (1991) 0.75
[Enoxacin: spectrum and activity of its antibacterial effect]. Infection (1986) 0.75
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
[Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)]. Infection (1977) 2.54
Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother (1979) 2.23
Clinical evaluation of a Mycobacterium tuberculosis PCR assay. J Clin Microbiol (1995) 2.19
Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J (1996) 2.18
A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed (1980) 2.03
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00
Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med (1989) 1.99
67 Ga for tumor scanning. J Nucl Med (1972) 1.97
Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest (1998) 1.95
High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol (1996) 1.81
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80
Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77
Application of the polymerase chain reaction in the diagnosis of pulmonary toxoplasmosis in immunocompromised patients. Eur J Clin Microbiol Infect Dis (1992) 1.71
High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur Respir J (2006) 1.64
Respiratory failure in patients undergoing allogeneic hematopoietic SCT--a randomized trial on early non-invasive ventilation based on standard care hematology wards. Bone Marrow Transplant (2011) 1.63
[Correlation of thromboplastin times in dicumarol treated patients using various preparations of thrombokinase]. Z Klin Chem Klin Biochem (1970) 1.53
Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J (1995) 1.52
Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects. Association with cell-binding ability and superoxide anion production. Am Rev Respir Dis (1992) 1.49
Hypersensitivity pneumonitis associated with the use of temozolomide. Eur Respir J (2009) 1.47
Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther (1980) 1.46
[Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance]. Dtsch Med Wochenschr (2008) 1.45
Pharmacodynamics of fluoroquinolones. Clin Infect Dis (1998) 1.42
Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother (1982) 1.42
Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother (1996) 1.40
Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother (1983) 1.39
Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J Clin Virol (2004) 1.39
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis (2001) 1.37
Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J (2006) 1.29
Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother (1984) 1.28
Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J (2006) 1.28
Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis (2000) 1.27
[Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother (1975) 1.26
Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J (2003) 1.24
Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother (1999) 1.24
Comparative pharmacokinetics of new quinolones. Drugs (1987) 1.22
Reliability of drug history in analgesic users. Lancet (1984) 1.21
Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1982) 1.19
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother (1996) 1.19
Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis (1992) 1.17
Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol (1989) 1.12
Localized pulmonary infection associated with Mycobacterium tilburgii in an HIV-infected patient. Infection (2005) 1.12
[Congenital nonspherocytic hemolytic anemia, cataract and glucose-6-phosphate dehydrogenase deficiency]. Dtsch Med Wochenschr (1966) 1.11
Determination of cefmenoxime in human body fluids by high-performance liquid chromatography. Eur J Clin Microbiol (1983) 1.08
Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother (1983) 1.07
Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med (1997) 1.05
Amplification of Mycobacterium tuberculosis from peripheral blood. J Clin Microbiol (1995) 1.03
Toxicity of quinolones. Drugs (1999) 1.03
Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother (1983) 1.03
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother (1992) 1.02
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother (2000) 1.01
Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis (1996) 1.01
Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother (1992) 1.00
Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother (1983) 0.99
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother (2001) 0.99
Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr (1979) 0.99
Measurement of lung density by computed tomography. J Comput Assist Tomogr (1978) 0.99
Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. Antimicrob Agents Chemother (1998) 0.99